FDA’s Oncologic Drugs Advisory Cmte. Will Review Avastin In Breast Cancer Dec. 5
This article was originally published in The Pink Sheet Daily
Executive Summary
ODAC will address Genentech’s sBLA for bevacizumab in combination with paclitaxel for patients who have not received chemotherapy for locally recurrent or metastatic HER2 negative breast cancer.
You may also be interested in...
EMEA’s CHMP Recommends Approval For Avastin In Kidney Cancer
Renal cell cancer would be the fourth indication gained in the EU for the VEGF-inhibitor; Genentech plans to submit an sBLA for kidney cancer in 2008.
EMEA’s CHMP Recommends Approval For Avastin In Kidney Cancer
Renal cell cancer would be the fourth indication gained in the EU for the VEGF-inhibitor; Genentech plans to submit an sBLA for kidney cancer in 2008.
Avastin sBLA For Metastatic Breast Cancer Gets Advisory Committee Review
Genentech reports that FDA has accepted its resubmitted application, which will be reviewed by the Oncologic Drugs Advisory Committee in December.